Advanced in Glomus Jugulare Tumor

Dr. Michelle L. Mierzwa

Radiation Oncology
Regents Of The University Of Michigan
1500 E Medical Ctr Dr, 
Ann Arbor, MI 
Accepting New Patients
Offers Telehealth
Advanced in Glomus Jugulare Tumor
Regents Of The University Of Michigan
1500 E Medical Ctr Dr, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michelle Mierzwa is a Radiation Oncologist in Ann Arbor, Michigan. Dr. Mierzwa is rated as an Advanced provider by MediFind in the treatment of Glomus Jugulare Tumor. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Dry Mouth, and Pancreaticoduodenectomy. Dr. Mierzwa is currently accepting new patients.

Her clinical research consists of co-authoring 100 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in OH
Hospital Affiliations
University Of Michigan Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr Dr, Ann Arbor, MI 48109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multi-Center Phase II Trial of Individualized Adaptive De-escalated Radiotherapy Using Pre and Mid-Treatment FDG-PET/CT for HPV-related Oropharynx Cancer
A Multi-Center Phase II Trial of Individualized Adaptive De-escalated Radiotherapy Using Pre and Mid-Treatment FDG-PET/CT for HPV-related Oropharynx Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel
Study Phase: Phase 2
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: February 29, 2024
Intervention Type: Radiation, Drug
Study Drug: Cetuximab
Study Phase: Phase 2
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
Enrollment Status: Unknown
Publish Date: August 31, 2023
Intervention Type: Radiation, Drug
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
Phase I Study to Evaluate the Feasibility of Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body
Phase I Study to Evaluate the Feasibility of Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body
Enrollment Status: Completed
Publish Date: April 29, 2022
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 5 Less Clinical Trials

100 Total Publications

Correction to: Survivorship therapy needs after radiotherapy for head and neck cancer: surveying opportunities for growth (STRONG).
Correction to: Survivorship therapy needs after radiotherapy for head and neck cancer: surveying opportunities for growth (STRONG).
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: June 12, 2025
Similar Doctors
Advanced in Glomus Jugulare Tumor
Dr. Peter Y. Chen
Radiation Oncology
Advanced in Glomus Jugulare Tumor
Dr. Peter Y. Chen
Radiation Oncology

Beaumont Medical Group- Specialty Services

28100 Grand River Ave, 
Farmington Hills, MI 
 (23.5 miles away)
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Peter Chen is a Radiation Oncologist in Farmington Hills, Michigan. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Acoustic Neuroma, Intraductal Papilloma, Laryngeal Cancer, Schwannoma, and Gamma Knife Radiosurgery. Dr. Chen is currently accepting new patients.

Advanced in Glomus Jugulare Tumor
Dr. Daniel R. Wahl
Radiation Oncology
Advanced in Glomus Jugulare Tumor
Dr. Daniel R. Wahl
Radiation Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (0.1 miles away)
734-936-4300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Wahl is a Radiation Oncologist in Ann Arbor, Michigan. Dr. Wahl is rated as an Elite provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, and Glioma. Dr. Wahl is currently accepting new patients.

Advanced in Glomus Jugulare Tumor
Dr. Shruti W. Jolly
Radiation Oncology
Advanced in Glomus Jugulare Tumor
Dr. Shruti W. Jolly
Radiation Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (0.1 miles away)
734-936-4300
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Shruti Jolly is a Radiation Oncologist in Ann Arbor, Michigan. Dr. Jolly is rated as a Distinguished provider by MediFind in the treatment of Glomus Jugulare Tumor. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adrenal Cancer, and Pleuropulmonary Blastoma. Dr. Jolly is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mierzwa's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile